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The Huntington’s disease (HD) CAG repeat, encoding a polymorphic glutamine tract in huntingtin, is inversely
correlated with cellular energy level, with alleles over ;37 repeats leading to the loss of striatal neurons. This early HD
neuronal specificity can be modeled by respiratory chain inhibitor 3-nitropropionic acid (3-NP) and, like 3-NP, mutant
huntingtin has been proposed to directly influence the mitochondrion, via interaction or decreased PGC-1a expression.
We have tested this hypothesis by comparing the gene expression changes due to mutant huntingtin accurately
expressed in STHdh
Q111/Q111 cells with the changes produced by 3-NP treatment of wild-type striatal cells. In general,
the HD mutation did not mimic 3-NP, although both produced a state of energy collapse that was mildly alleviated by
the PGC-1a-coregulated nuclear respiratory factor 1 (Nrf-1). Moreover, unlike 3-NP, the HD CAG repeat did not
significantly alter mitochondrial pathways in STHdh
Q111/Q111 cells, despite decreased Ppargc1a expression. Instead, the
HD mutation enriched for processes linked to huntingtin normal function and Nf-jB signaling. Thus, rather than a
direct impact on the mitochondrion, the polyglutamine tract may modulate some aspect of huntingtin’s activity in
extra-mitochondrial energy metabolism. Elucidation of this HD CAG-dependent pathway would spur efforts to achieve
energy-based therapeutics in HD.
Citation: Lee JM, Ivanova EV, Seong IS, Cashorali T, Kohane I, et al. (2007) Unbiased gene expression analysis implicates the huntingtin polyglutamine tract in extra-
mitochondrial energy metabolism. PLoS Genet 3(8): e135. doi:10.1371/journal.pgen.0030135
Introduction
The CAG trinucleotide repeat in the Huntington’s disease
gene (HD) is highly polymorphic in humans, with alleles
ranging from ;6t o.100 units encoding a variable polyglut-
amine tract in huntingtin, a large (.350 kDa) HEAT domain
protein [1]. The gene was discovered because alleles over
;35–37 units, whether inherited in one copy or, in rare cases,
two copies, are associated with the onset of Huntington’s
disease (HD) symptoms, including dance-like movements,
cognitive decline, and psychiatric disturbance [1]. This
intriguing disease-initiating mechanism, while relatively
insensitive to dosage, is exquisitely progressive with allele
size, such that the age at onset of HD symptoms is
progressively decreased as CAG length is increased [1].
The early HD pathology comprises the selective loss of
medium-size spiny neurons in the striatum that forms the HD
pathological grading system [2]. The ability of mitochondrial
respiratory chain poisons such as succinate dehydrogenase
inhibitor 3-nitropropionic acid (3-NP) to produce HD-like
striatal-speciﬁc cell loss has implied a role for mitochondrial
dysfunction in HD pathogenesis [3]. Indeed, numerous
studies have demonstrated that deﬁcits in measures of energy
metabolism become manifest in presymptomatic and symp-
tomatic HD brain and peripheral tissues [4–11].
Investigations of the early consequences of the HD CAG
repeat in human lymphoblastoid cell lines have recently
implicated the polyglutamine tract size in huntingtin in
modulating cellular ATP/ADP ratio across the entire non-HD
and HD range [12]. The longest alleles were associated with
the lowest ATP/ADP ratios, while alleles in the non-HD range
were associated with progressively higher energy levels [12].
Moreover, consistent with a role for the polyglutamine tract
in inﬂuencing an intrinsic huntingtin function in energy
metabolism, the targeted deletion of the short seven-
glutamine tract from murine huntingtin yielded elevated
cellular ATP, with early senescence, and improved motor
performance in Hdh
DQ/DQ mice [13].
The shared downstream consequences of the HD CAG tract
and 3-NP have implied that the polyglutamine tract in
huntingtin, like 3-NP, may directly affect the mitochondrion
[14]. Huntingtin is detected throughout the cell, in the
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mitochondria [15], implicating a direct ‘‘toxic’’ interaction
[15–17]. However, recent ﬁndings, including studies in
STHdh
Q111/Q111 striatal cells, with a knock-in juvenile onset
CAG repeat accurately expressed as endogenous huntingtin
with 111 glutamines [18], suggested that mutant huntingtin
may inﬂuence mitochondrial biogenesis/function by decreas-
ing Ppargc1a transcription [19,20]. This gene encodes perox-
isome proliferative activated receptor gamma, coactivator 1
alpha (PGC-1a), a key cofactor for Nrf-1 and other
mitochondrial transcription regulators.
To probe the earliest consequences of the HD CAG
mechanism, we tested the mitochondrial hypothesis by using
unbiased gene expression analysis to monitor the extent to
which the accurate expression of the HD CAG repeat, in
STHdh
Q111/Q111 striatal cells, may reproduce the consequences
of 3-NP challenge. The results conﬁrmed a shared down-
stream energy collapse but did not indict direct 3-NP-like
effects of the HD CAG repeat on the mitochondrion. Instead,
the data have elevated the candidacy of extra-mitochondrial
pathways in huntingtin modulation of energy metabolism.
Result/Discussion
We and others have demonstrated previously that
STHdh
Q111/Q111 cells, compared to wild-type STHdh
Q7/Q7 cells
(expressing endogenous seven-glutamine huntingtin), ex-
hibited mitochondrial energy phenotypes similar to the
effects of 3-NP treatment, including decreased mitochondrial
respiration [21] and ATP synthesis [12,21,22]. However,
STHdh
Q111/Q111 cells also have been shown to display
phenotypes opposite to the effects reported for 3-NP
challenge, such as increased, instead of decreased, levels of
the reactive oxygen species (ROS) scavenger glutathione [23],
suggesting that 3-NP might not precisely mimic the effects of
the HD mutation.
To explore this notion, we examined additional energy
phenotypes and observed, as reported for 3-NP challenge,
that the HD mutation decreased mitochondrial membrane
potential (Figure 1A) and elevated the lactate/pyruvate ratio
(Figure 1B) indicative of altered energy homeostasis. Indeed,
in human lymphoblastoid cells, this ratio was increased in
severity with HD CAG repeat size (Figure 1C), demonstrating
that mitochondrial dysfunction is likely to be a consequence
of the HD CAG size-dependent mechanism. However, while 3-
NP, as reported [24], was associated with increased ROS, as
measured by hydrogen peroxide levels, the STHdh
Q111/Q111
cells, compared to wild-type cells, exhibited decreased ROS
(Figure 1D). Moreover, while 3-NP treated wild-type cells, as
expected, displayed decreased succinate dehydrogenase
activity, the longer HD CAG repeat expressed in the
STHdh
Q111/Q111 cells did not signiﬁcantly change the activity
Figure 1. Mitochondrial Phenotypes Altered by the HD Mutation or 3-NP
Treatment
(A) Mitochondrial membrane potential, denoted by the FL1/FL2 ratio,
was significantly decreased by the HD mutation in STHdh
Q111/Q111 cells
(ST111/111), compared to wild-type STHdh
Q7/Q7 cells (ST7/7).
(B) Lactate/pyruvate ratio was significantly increased in both
STHdh
Q111/Q111 cells (ST111/111) and 3-NP treated wild-type STHdh
Q7/Q7
cells (ST7/7 þ 3-NP), compared to untreated STHdh
Q7/Q7 cells (ST7/7).
(C) Lactate/pyruvate ratio was significantly increased in HD lympho-
blastoid cells as the length of the longer of the two HD CAG alleles was
increased, from the typical normal size (18 CAG) to the adult onset HD
(42–50 CAG) and juvenile onset HD (66–70) ranges.
(D) ROS, monitored by hydrogen peroxide concentration, was signifi-
cantly decreased in STHdhQ111/Q111 cells (ST111/111) compared to
STHdh
Q7/Q7 cells (ST7/7) but was dramatically increased in wild-type
cells following treatment with 3-NP.
(E) Succinate dehydrogenase activity was similar in STHdh
Q111/Q111 cells
(ST111/111) and STHdh
Q7/Q7 cells (ST7/7), but was significantly decreased
by 3-NP treatment of wild-type STHdh
Q7/Q7 cells (ST7/7 þ 3-NP).
In all panels, asterisk denotes significant difference (p , 0.05) from ST7/7
by Student t-test.
doi:10.1371/journal.pgen.0030135.g001
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Author Summary
Huntington’s disease (HD) is a tragic neurodegenerative disorder
caused by a CAG repeat that specifies the size of a glutamine tract in
the huntingtin protein, such that the longer the tract, the earlier the
loss of striatal brain cells. A correlation of polyglutamine tract size
has also implicated huntingtin in the proper functioning of
mitochondria, the cell’s energy factories. Here we have tested the
prevailing hypothesis, that huntingtin may directly affect the
mitochondrion, by using comprehensive gene expression analysis
to judge whether the HD mutation may replicate the effects of 3-
nitropropionic acid (3-NP), a compound known to inhibit mitochon-
dria, with loss of striatal neurons. We found that, while mutant
huntingtin and 3-NP both elicited energy starvation, the gene
responses to the HD mutation, unlike the responses to 3-NP, did not
highlight damage to mitochondria, but instead revealed effects on
huntingtin-dependent processes. Thus, rather than direct inhibition,
the polyglutamine tract size appears to modulate some normal
activity of huntingtin that indirectly influences the management of
the mitochondrion. Understanding the precise nature of this extra-
mitochondrial process would critically guide efforts to achieve
effective energy-based therapeutics in HD.of this respiratory chain component (Figure 1E). Thus, while
superﬁcially similar, the energy phenotypes displayed by
mutant striatal cells did not in detail recapitulate the effects
of 3-NP challenge, implying distinct underlying pathways.
To delineate the effects of the HD CAG repeat and 3-NP
treatment, without making a priori assumptions about the
underlying biology, we performed global analysis to monitor
the expression of the mitochondrial and the nuclear genomes.
As sequences for genes located on the mitochondrial genome
were not represented on the murine Affymetrix MG 430 2.0
arrays microarrays, which we used to analyze the nuclear
genome (below), the expression of nine of the 13 mitochon-
drial genes encoding respiratory components was assessed
using speciﬁc RT-PCR assays. The mRNA levels for each of
these genes was dramatically reduced in 3-NP treated cells,
compared to untreated wild-type striatal cells, whereas mRNA
levels did not differ signiﬁcantly between STHdh
Q111/Q111 and
wild-type cells (Figure S1). Thus, consistent with unchanged
succinate dehydrogenase activity, mutant huntingtin did not
reproduce the effects of 3-NP on the mitochondrial genome,
implying that the energy deﬁcits in STHdh
Q111/Q111 cells might
instead stem from altered expression of the nuclear genes that
regulate the mitochondrion.
We then performed unbiased analysis of the nuclear
Figure 2. HD CAG Mutation and 3-NP Treatment Produced Distinct Signatures
(A) Plot of unsupervised principal component analysis of triplicate datasets for wild-type striatal cells (ST7/7/), mutant striatal cells (ST111/111), and wild-
type cells treated with 3-NP (ST7/7þ3-NP), revealing discrete gene expression space for the HD CAG repeat (comparison of ST111/111 and ST7/7) and 3-
NP treatment (comparison of ST7/7þ3-NP and ST7/7).
(B) Dendrogram plot, generated by average linkage clustering algorithm analysis of the expression values of all probes, indicated proper clusteringo f
triplicate samples within each group and revealed that the mutant cell group (ST111/111) was more closely related to the wild-type cell group (ST7/7)
than to the 3-NP treated wild-type cell samples (ST7/7þ3-NP). Arrows depict the data set comparisons to generate changes due to the HD CAG and 3-
NP treatment.
(C) Diagram summarizing the identification of significantly altered probe signals using a stringent FDR q-value 0.005, which revealed 630 probes
different between mutant and wild-type striatal cells (HD CAG) and 889 probes changed between wild-type cells and wild-type cells treated with 3-NP
(3-NP), with 83 probes significant in both comparisons (shared). Of these, 70 % were concordantly changed.
(D) Plot of the correlation coefficients between the HD CAG- and 3-NP-changes for all probes (white), for the HD CAG significant probes (red), and for
the 3-NP significant probes (green), demonstrating the distinct nature of the changes in the two comparisons.
(E) Volcano plots of fold-change versus FDR q-value for probes significant (q , 0.005) in the HD CAG comparison (red) and those same probes in the 3-
NP comparison (green) (left panel) or the converse (right panel), showing the small overlap and more dynamic expression changes for the HD CAG
repeat, compared to 3-NP treatment.
doi:10.1371/journal.pgen.0030135.g002
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HD CAG Does Not Directly Inhibit the Mitochondriongenome expression datasets to determine the extent to which
the consequences of the HD CAG repeat may mirror the
effects of 3-NP challenge. The results of principle component
(Figure 2A) and cluster analysis (Figure 2B) of all probes
demonstrated that, whereas the replicate datasets were highly
related, the wild-type, 3-NP treated, and mutant cell datasets
were quite distinct. Thus, rather than giving rise to similar
effects, which may differ in magnitude, the consequences of
the HD CAG repeat and 3-NP appeared to be fundamentally
different. Indeed, at a stringent false discovery rate (FDR) (q
, 0.005), approximately the same proportion of all probes
(3%) was signiﬁcantly altered either by the HD CAG repeat
mutation (comparing mutant versus wild-type cells) (Table
S1) or by 3-NP challenge (comparing 3-NP treated wild-type
versus wild-type cells) (Table S2), with the HD CAG yielding
some changes of larger magnitude (fold-change) than 3-NP.
However, little overlap was detected between the two probe
lists (summarized in Figure 2C and 2E), yielding low
correlation coefﬁcients between HD CAG and 3-NP changed
probes (Figure 2D). Indeed, for the most part, these
represented different genes, which are plotted by chromo-
some in Figure S2. Thus, while the impact, in terms of
number and magnitude of changes, was similar, HD mutation
did not reproduce the molecular effects of 3-NP.
The mitochondrial hypothesis predicted that both the HD
mutation and 3-NP treatment would alter mitochondrial
energy genes, prompting an examination of the small fraction
(0.18%) of all probes signiﬁcantly altered by both insults.
These represented 83 known genes (plotted by chromosome
in Figure S3 and listed in Table S3), which did not highlight
the mitochondrion but instead spotlighted decreased cyto-
solic energy production (Figure 3). More sensitive tests of
groups of genes in functional pathways, using the Gene
Ontology (GO) biological process (Figure 4A) and sigPathway
gene set analysis [25] (Figure 4B), conﬁrmed that the HD
m u t a t i o na n d3 - N Pw e r eb o t ha s s o c i a t e dw i t hh i g h l y
signiﬁcant decreases in carbohydrate metabolism and, as
reported previously [26], lipid (sterol/cholesterol) biosynthesis
(Figure 4C). Thus, striatal cells, unlike glia or other cell types,
may possess a limited capacity to adjust glycolytic ﬂux in
response to changes in mitochondrial ATP synthesis [27],
thereby providing a potential explanation for the ability of 3-
NP to mimic the early loss of striatal neurons in HD striatum.
Although the notion that the HD mutation and 3-NP might
commonly alter the expression of nuclear encoded mito-
chondrial genes did not appear to be borne out, inspection of
the data did reveal signiﬁcant changes in a few mitochondria-
related energy genes in mutant striatal cells, which, notably,
were unchanged by 3-NP (Figure 3). Ppargc1a (encoding PGC-
1a) was decreased, as reported previously [19]. Mitochondrial
components in the transfer electrons from NADH to the
respiratory chain (Ndufa12 and Ndufa3) or in the transport of
hydrogen ions (Atp6v0e2) were decreased. By contrast, mRNAs
encoding the iron sulfur-binding factor of complex III (Uqcr)
and a nonenzymatic component of the ATP synthase complex
(Atp5j2) were elevated. Moreover, consistent with elevated
glutathione [23], the expression of genes that detoxify free
radical derivatives (Ldh2, Gss, and Glo1) was increased,
suggesting that altered redox state may contribute distinctly
to low energy (and lipid) metabolism in mutant striatal cells.
The decrease in Ppargc1a mRNA implied that mitochon-
drial regulatory transcription factors such as Nrf-1, which are
coregulated by PGC-1a, might be expected to improve energy
metabolism in mutant cells. Indeed, over-expression of Nrf-1
in STHdh
Q111/Q111 cells altered the mRNA levels of known Nrf-
1 target genes (Table S4) but, as reported for PGC-1a 19], only
mildly improved both cellular lactate/pyruvate ratio (Figure
5A) and cell survival following respiratory chain inhibition
(Figure 5B). Thus, coupled with the apparent dearth of
changes in mitochondrial factors, the modest effects of
boosting Nrf-1 strongly suggested that mutant huntingtin
may not directly perturb the mitochondrion.
Consequently, to more rigorously examine this possibility,
we used gene set enrichment analysis (GSEA) to speciﬁcally
determine whether mitochondrial pathways or processes may
be perturbed by 3-NP or the HD mutation. GSEA examines,
as a group, genes that form a functional pathway, thereby
capturing small effect sizes that when considered in single
gene analyses may not have reached our stringent statistical
threshold. We tested two sets of ;1,500 nuclear genes that
were either GO annotated or predicted by the integrative
Figure 3. HD CAG and 3-NP Shared Decreased Expression of Glycolytic
Genes
The energy metabolism pathway gene expression changes common to
mutant striatal cells (HD CAG, red) and 3-NP treated wild-type striatal
cells (3-NP, green) are shown, with fold-change, compared to wild-type
striatal cells, highlighting decreased cytosolic glycolytic processes
(numbered 1–11). The HD mutation but not 3-NP treatment was
associated with increased expression of Ldh2 and of enzymes in the
formation and breakdown of glutathione or the toxic product
methylglyoxyal. Single asterisk denotes FDR q-value ,0.05 double
asterisks denote FDR q-value , 0.005.
doi:10.1371/journal.pgen.0030135.g003
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HD CAG Does Not Directly Inhibit the Mitochondriongenomics program MAESTRO [28] to encode mitochondrial
products, as well as a third set comprising the group of 902
genes that were common to both lists (Table S5; Figure 6A
and 6B). The GSEA results, plotted as enrichment scores in
Figure 6C, demonstrated that, compared to wild-type cells,
each of the gene sets was highly enriched by 3-NP treatment.
In striking contrast, no signiﬁcant enrichment of any of the
mitochondrial gene sets was detected in STHdh
Q111/Q111 cells.
Thus, these ﬁndings, which were consistent with the results of
the mitochondrial genome analysis (Figure S1), clearly
revealed that the HD mutation did not reproduce the direct
effects of 3-NP on the mitochondrion. Therefore, contrary to
predictions from decreased Ppargc1a mRNA or interactions
of mutant huntingtin with the mitochondrion [14–17,19,20],
Figure 4. Pathways Common to HD CAG and 3-NP Reveal Decreased Carbohydrate and Lipid Metabolism, with HD CAG-Specific Pathways Reminiscent
of huntingtin Normal Function
(A) Venn diagrams summarize the results of GO analysis (biological process), showing the numbers of significantly altered (Increase, Decrease) HD CAG-
specific, 3-NP-specific and shared GO terms, with the major categories of pathways listed below.
(B) Venn diagram, statistical criteria, and NTk value-based heatmap summarize the results of sigPathway analysis to distinguish gene sets that were HD
CAG specific (Group 1), 3-NP specific (Group 5), or highly significant in both the HD CAG and 3-NP comparisons (Group 3). Groups 2 and 4 were judged
marginally significant. High absolute NTk value indicates high significance andþNTk and –NTk denote enrichment in the control group (ST7/7) and the
experimental group (ST111/111 or ST7/7þ3-NP), respectively. The major categories of enriched gene sets, with the direction of change denoted by
arrows, are listed.
(C) A list of the 15 pathways that were found to be common to the HD mutation and 3-NP treatment, as judged significant in both GO and sigPathway
analysis. All were enriched in wild-type cells (ST7/7) compared to mutant striatal cells or 3-NP treated wild-type cells and denoted glycolysis and lipid/
sterol metabolism.
doi:10.1371/journal.pgen.0030135.g004
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HD CAG Does Not Directly Inhibit the Mitochondrionour results consistently implied that the HD CAG mechanism
may primarily inﬂuence energy metabolism via extra-mito-
chondrial cellular pathways.
Since our data supported the view that the processes by
which the HD mutation and 3-NP may lead to energy
starvation were largely distinct, we reasoned that the path-
ways that did mediate the effects of the huntingtin polyglut-
amine tract would be those that were not affected by 3-NP
challenge. To support this approach, we tested whether the
early presymptomatic consequences of the HD CAG repeat in
medium-size spiny striatal neurons in vivo might be reca-
pitulated by accurate expression of the expanded HD CAG
repeat in cultured STHdh
Q111/Q111 cells or by 3-NP challenge
of wild-type cells. Microarray analysis of mRNA from
medium-size spiny striatal neurons, obtained by laser capture
microscopy (LCM) from post-mortem brain, has been
reported [29]. The major class of LCM genes judged to be
the most signiﬁcantly altered by the HD CAG in that study, all
with decreased expression, yielded a set of 38 mouse genes
(Table S14) that were tested by GSEA in our striatal cell HD
CAG and 3-NP datasets. The results demonstrated that this
human LCM gene set was signiﬁcantly decreased in the
STHdh
Q111/Q111 cells (enrichment score [ES] 0.51, p-value 0.000,
FDR q-value 0.180) but was not altered in the 3-NP treated
cells (ES 0.38, p-value 0.271, FDR q-value 0.713). Thus, the
early molecular consequences of the HD CAG repeat in
striatal neurons in human brain also become manifest as a
consequence of accurate expression of the expanded repeat
in the cultured STHdh
Q111/Q111 cells but these were not
reproduced by 3-NP challenge. This supported the approach
of attempting to identify the processes by which huntingtin
may modulate energy metabolism by examination of HD CAG
repeat–speciﬁc changes.
Therefore, stringent statistical ﬁltering criteria were used
to identify those gene sets that were enriched in mutant
striatal cells but not in 3-NP treated wild-type cells (Tables
S6–S12). Remarkably, a major class of pathways uniquely
enriched in STHdh
Q111/Q111 cells, summarized in Figure 4A
and 4B, pointed to processes implicated in huntingtin’s
essential normal activities [30–33]: development/morpho-
genesis (central nervous system, mesoderm, and embryo);
growth, cell motility, migration, and locomotion; cell adhe-
sion; neuronal processes; and TGF-b and BMP signaling. A
minor class, which denoted increased gap junction channel
(connexin), phosphate, and anion transport, may also prove
to be related to huntingtin function. These results, therefore,
strongly implicated huntingtin normal function in the capac-
ity of the polyglutamine tract to inﬂuence mitochondrial
function and cellular energy metabolism in STHdh
Q111/Q111
cells.
Notably, this ﬁnding is consistent with a genetic gain-of-
function hypothesis for the mechanism that initiates the HD
pathogenic process. The polyglutamine tract size may
Figure 5. Nrf-1 Ameliorated Mutant Striatal Cell Lactate/Pyruvate and
Survival
(A) Bar plot of lactate/pyruvate ratio in STHdh
Q111/Q111 striatal cells
transiently transfected with pSG5 control plasmid (white) or Nrf-1
expression plasmid (black), demonstrating improvement with the latter.
Asterisk denotes p , 0.05 by Student’s t-test.
(B) Bar plot of viability of STHdh
Q111/Q111 cells that were transiently
transfected with control pSG5 plasmid (white) or Nrf-1 plasmid (black),
challenged with various concentrations of 3-NP, showing increased
survival with the latter. Asterisk denotes p , 0.05 by Student’s t-test.
doi:10.1371/journal.pgen.0030135.g005
Figure 6. 3-NP but Not the HD mutation altered Nuclear-Encoded
Mitochondrial Gene Expression
(A) Venn diagram depicting the numbers of probes in two overlapping
nuclear gene sets, either annotated by GO cellular component (GO) or
predicted by MAESTRO [28] to encode mitochondrial gene products,
with those identified in both procedures forming a third gene set
(Overlap).
(B) Bar plot of probe number percentage versus FDR q-value for each of
the mitochondrial probe sets (MAESTRO, GO, overlap) revealed that
fewer mitochondrial components were altered in the HD CAG
comparison (red) than in the 3-NP comparison (green), with only a
small subset concordantly altered by both insults (yellow).
(C) Plots of GSEA ranked metric and ES revealed that in each case the
mitochondrial gene sets were significantly enriched only in wild-type
cells treated with 3-NP (ST7/7þ3-NP) and not in mutant striatal cells
(ST111/111), compared to wild-type striatal cells (ST7/7).
doi:10.1371/journal.pgen.0030135.g006
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HD CAG Does Not Directly Inhibit the Mitochondrionprogressively inﬂuence energy homeostasis by increasing
some intrinsic huntingtin activity. Alternatively, it may
capitalize on an opportunity afforded by huntingtin function
to modulate an unrelated cellular component.
What might this normal huntingtin activity be? One
possibility, inferred from previous work with huntingtin-
deﬁcient cells [34,35], as well as with STHdh
Q111/Q111 cells [18],
may reﬂect a role for huntingtin in intracellular iron
trafﬁcking. However, huntingtin’s normal activities impact a
broad range of cellular processes, from vesicle trafﬁcking to
the proper regulation of gene transcription [33,36,37]. As a
starting point, therefore, we reasoned that worthy candidates
for huntingtin modulation of energy metabolism might be
found among the transcriptional regulators that most
frequently orchestrate the gene changes in STHdh
Q111/Q111
cells, but not 3-NP treated cells.
Unbiased transcription factor analysis coupled with GSEA
yielded ﬁve HD CAG–speciﬁc candidates (Figure 7). Interest-
ingly, NRSF/REST, associated with altered expression of genes
in STHdh
Q111/Q111 cells and in HD brain [37], did not emerge
as a candidate, and NRSF/REST target genes or genes with
upstream RE1 binding sites were not enriched as a
consequence of the HD CAG repeat (unpublished data). The
top candidates for HD CAG speciﬁc regulators were CAAT-
Box (e.g., NF-Y, cEBP, and CTF) and nuclear factor kappa B
(Nf-jB), with weaker support for Nrf-1 and Sp-1. Most of
these candidates, including Nrf-1, have been shown to exert
extra-mitochondrial effects on energy metabolism, affecting,
e.g., fatty oxidation, glycolysis, glutathione synthesis, and cell
stress-sensing [38–40]. Moreover, by associating exclusively
with mutant huntingtin (or fragment), PGC-1a, a coregulator
with Nrf-1, Sp-1, and its coregulator TAF4, as well as core
components of Pol II transcriptional machinery (TFIID,
TFIIF) have been implicated in HD pathogenesis [19,41–43].
However, the mechanism by which the HD CAG modulates
cellular energy levels was manifest even at non-HD-causing
lengths, in the cadre of normal huntingtin function [12]. Nf-
jB/Dorsal/RelB has been linked previously to huntingtin’s
normal function [44]. Nf-jB was a modiﬁer of huntingtin
carboxyl terminal fragment–induced phenotypes in Drosophi-
la [44]. Furthermore, endogenous normal human huntingtin
can associate with the p50 subunit of Nf-jB [44], which binds
to target gene promoters in a redox-dependent manner [45].
This raises a new hypothesis that merits investigation in a
variety of suitable polymorphic HD CAG systems, namely,
that huntingtin polyglutamine tract length may inﬂuence Nf-
jB-mediated signaling, perhaps via redox sensing, either as a
cause or a consequence of modulating energy metabolism.
In summary, the results of this study demonstrated that the
early (presymptomatic) consequences of the juvenile onset
HD CAG allele, accurately expressed in STHdh
Q111/Q111 striatal
cells, did not in most details mimic mitochondrial respiratory
chain inhibitor 3-NP, although both metabolic challenges
produced a common response—the collapse of mitochon-
drial and cytosolic energy processes. This reveals the limited
utility of 3-NP lesion models for uncovering the pathways by
which the polyglutamine tract in huntingtin may inﬂuence
energy metabolism or for prioritizing agents that may modify
these processes. Indeed, the data uniformly refute the widely
held view of a direct mutant huntingtin-speciﬁc effect on the
mitochondrion. Instead, our data implicate an effect of the
polyglutamine tract on some normal activity of the hunting-
tin protein in extra-mitochondrial energy metabolism,
perhaps redox sensing.
It is interesting to note that redox sensing cell signaling, via
ROS-dependent pathways, is emerging as a regulator of
glucose and lipid metabolism in health, aging, and disease
[46]. If huntingtin proves to be involved, the molecules and
gene products that modify oxidation-sensitive signaling in
metabolic disorders may become candidates for modifying
huntingtin-regulated mitochondrial metabolism in HD. By
the same token, agents that modify redox sensing signaling in
HD may also be of interest in cancer and a variety of complex
metabolic disorders.
Materials and Methods
Cell culture and 3-NP treatment. STHdh
Q7/Q7 and STHdh
Q111/Q111
cells, generated from striatal primordia of wild-type Hdh
Q7/Q7 and
homozygous mutant Hdh
Q111/Q111 knock-in mouse embryos, respec-
tively [18], were cultured in DMEM (33 8C, 5% CO2, 10% FBS, and 400
lg/ml G418). Challenge of STHdh
Q7/Q7 cells with 3-NP (1 mM) was for
48 h. Previously genotyped human lymphoblastoid cell lines (HD CAG
17/18, 15/42, 21/43, 21/66, 19/70, 41/48, and 45/50) were cultured in
RPMI-1640 (37 8C, 5% CO2, and 5% FBS).
Mitochondrial membrane potential, succinate dehydrogenase
activity, ROS, and lactate/pyruvate ratio. Mitochondrial membrane
potential was measured by incubation of cells with JC-1 (2.5 lg/ml) for
20 min at 33 8C, followed by ﬂow cytometry (FACScalibur, http://www.
bdbiosciences.com/), counting 10
4 cells in the FL1 (monomer) and
FL2 (aggregate) channels and calculating FL2/FL1 ratio.
Succinate dehydrogenase activity, measured using succinate as a
substrate and 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphen-
yl)-2-(4-sulfophenyl)-2H-tetrazolium as an electron acceptor, was
normalized by protein concentration [47]. ROS levels were monitored
by determinations of hydrogen peroxide concentration, using a
chemiluminescent hydrogen peroxide detection kit (Assay Designs,
http://www.assaydesigns.com/). Data were quantiﬁed compared to a
standard curve, and normalized to cell number. Lactate and pyruvate
concentrations in cleared lysates (3% perchloric acid, sonication)
were determined by HPLC analysis (Aminex column, Bio-Rad
Laboratories, http://www.bio-rad.com/; 0.6 ml/min 0.05 mM H2SO4;
UV detection at 210 nm) using appropriate standards. All measure-
ments derive from triplicate experiments, using duplicate samples.
Data are given as the mean, þ/  one standard deviation.
Mitochondrial genome gene expression analysis. Reverse tran-
scription PCR (RT-PCR) analysis for the genes listed in Table S5 was
performed (Bio-Rad iCycler) with gene-speciﬁc primer sets listed in
Table S13. The DDCT method was used to calculate gene expression
levels, compared to b-actin control [48].
Microarray analysis of nuclear genome gene expression. Total RNA
(5 lg), isolated from triplicate cell cultures, was converted using
SuperScript II reverse transcriptase (Invitrogen. http://www.
invitrogen.com) to labeled cRNA, and 25 lg of labeled probe was
hybridized to Affymetrix MG 430 2.0 arrays (http://www.affymetrix.
com). Expression data was generated and normalized using RMA [49]
and signiﬁcant probes were identiﬁed by FDR (q , 0.005) [50]. A
selection of genes judged to be signiﬁcantly altered according to
these criteria was tested by semi-quantitative RT-PCR analysis
(primer sets in Table S13), with ;80% (13 of 16 randomly chosen
genes) concordant with the microarray results. For pathway analysis,
signiﬁcant (p , 0.05) GO terms in signiﬁcantly altered probe sets were
identiﬁed by GO analysis (DAVID 2006) [51] and, using all probes,
signiﬁcantly enriched (q , 0.01) pathways were identiﬁed by
permutation-based GSEA (sigPathway) [25]. For the GSEA compar-
ison of the mouse and human presymptomatic striatal cell changes,
the LCM gene set comprised the 38 most robust LCM genes, all
decreased by the HD CAG repeat, drawn from the table in Hodges et
al. [29], that could be unambiguously mapped to a corresponding
mouse locus. Cluster [52], dChip [53], and Bioconductor [54] were
used for clustering and data visualization.
Nrf-1 transfection and cytotoxicity assay. STHdh
Q111/Q111 cells were
transiently transfected with control vector (pSG5) or Nrf-1 mamma-
lian cell expression plasmid (0.2 lg of plasmid/well) using lipofect-
amine as described by the manufacturer (Invitrogen). At 48 h post-
transfection, lactate/pyruvate ratios were determined, as described
above, and viability following 3-NP challenge was measured by MTS
cytotoxicity assay (Promega, http://www.promega.com/). Nrf-1 activity
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genes (Table S4), using semi-quantitative RT-PCR analysis with gene-
speciﬁc primer sets (Table S13).
Transcription factor analysis. For signiﬁcant genes, putative
transcription factor binding sites were identiﬁed from the MAPPER
database [55], by searching 500 bp upstream from the transcription
initiation site and then selecting the top ten transcription factors, by
score, for each gene. A total of 4,400 hits (358 transcription factors)
and 6,684 hits (371 transcription factors) were recorded for HD CAG
and 3-NP treatment, respectively, and the frequency for each was
then calculated relative to the total number of hits. As a statistical
test, the 100 top target genes for each transcription factor that
exhibited 2% or higher frequency in each comparison were identiﬁed
and used in the transcription factor analysis, to build a custom set for
gene set enrichment analysis [56].
Supporting Information
Figure S1. Mitochondrially Encoded Gene Expression Levels
Bar plot of mRNA levels, determined in RT-PCR assays, for nine
mitochondrially encoded genes encoding respiratory chain polypep-
tides in wild-type striatal cells (ST7/7), mutant striatal cells (ST111/
111), and wild-type striatal cells treated with 3-NP (ST7/7þ3-NP),
revealing decreased expression with 3-NP but not the HD mutation.
Found at doi:10.1371/journal.pgen.0030135.sg001 (33 KB PPT).
Figure S2. HD CAG and 3-NP Mostly Alter the Expression of
Different Genes
The signiﬁcant (FDR q , 0.005) gene changes associated with the HD
mutation in mutant versus wild-type striatal cells (HD CAG) or with 3-
NP treatment of wild-type cells versus untreated wild-type cells (3-
NP) are depicted by chromosomal location and can be viewed in
detail using probe ID (Tables S1 and S2) and dChip software [53].
Found at doi:10.1371/journal.pgen.0030135.sg002 (1.4 MB PPT).
Figure S3. Genes Altered by Both the HD CAG and 3-NP Treatment
The shared signiﬁcant (FDR q , 0.005) gene changes associated with
the HD mutation in mutant versus wild-type striatal cells (HD CAG)
or with 3-NP treatment of wild-type cells versus untreated wild-type
cells (3-NP) are depicted by chromosomal location and can be viewed
in detail using probe ID (Table S3) and dChip software.
Found at doi:10.1371/journal.pgen.0030135.sg003 (477 KB PPT).
Table S1. Probes Signiﬁcantly Altered by HD CAG
Found at doi:10.1371/journal.pgen.0030135.st001 (122 KB XLS).
Table S2. Probes Signiﬁcantly Altered by 3-NP Treatment
Found at doi:10.1371/journal.pgen.0030135.st002 (182 KB XLS).
Table S3. Probes Signiﬁcantly Altered by HD CAG and 3-NP
Treatment
Found at doi:10.1371/journal.pgen.0030135.st003 (30 KB XLS).
Table S4. Nrf-1 Target Gene Expression
Found at doi:10.1371/journal.pgen.0030135.st004 (30 KB DOC).
Table S5. Nuclear Genes Encoding Mitochondrial Components
Found at doi:10.1371/journal.pgen.0030135.st005 (275 KB XLS).
Table S6. Shared Signiﬁcant GO Terms by HD CAG and 3-NP
Comparison
Found at doi:10.1371/journal.pgen.0030135.st006 (47 KB DOC).
Table S7. HD CAG-Speciﬁc GO Terms
Found at doi:10.1371/journal.pgen.0030135.st007 (45 KB DOC).
Table S8. 3-NP-Speciﬁc GO Terms
Found at doi:10.1371/journal.pgen.0030135.st008 (147 KB DOC).
Table S9. Shared Gene Sets by HD CAG and 3-NP (Group 3)
Found at doi:10.1371/journal.pgen.0030135.st009 (33 KB DOC).
Table S10. HD CAG-Speciﬁc Gene Sets (Group 1)
Found at doi:10.1371/journal.pgen.0030135.st010 (34 KB DOC).
Table S11. 3-NP-Speciﬁc Gene Sets (Group 5)
Found at doi:10.1371/journal.pgen.0030135.st011 (165 KB DOC).
Table S12. Signiﬁcant Pathways Identiﬁed by Both GO Analysis and
Gene Set Analysis
Found at doi:10.1371/journal.pgen.0030135.st012 (60 KB DOC).
Table S13. Primer Sets for Gene-Speciﬁc PCR Assays
Found at doi:10.1371/journal.pgen.0030135.st013 (28 KB DOC).
Table S14. LCM-Derived Gene Set
Found at doi:10.1371/journal.pgen.0030135.st014 (22 KB XLS).
Accession Numbers
MIAME compliant microarray data were deposited at the Gene
Expression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo/) with
Accession number GSE3583.
Acknowledgments
We thank Kathryn Coser and Toshi Shioda of the Massachusetts
General Hospital Cancer Center Microarray Core for microarray
hybridizations, Sarah Calvo for assistance with MAESTRO, and
Richard Scarpulla for generously providing the Nrf-1 and control
expression plasmids.
Author contributions. JML, EVI, JFG, and MEM conceived and
designed the experiments. JML, EVI, and ISS performed the experi-
Figure 7. Transcription Factor Analysis to Identify HD CAG-Specific
Regulators
(A) A plot of the normalized frequency of putative transcription factor
binding sites identified from MAPPER database, for genes altered by the
HD mutation (HD CAG).
(B) A plot of the normalized frequency of putative transcription factor
binding sites identified from MAPPER database, for genes altered by 3-
NP treatment (3-NP).
(C) Results of GSEA of candidate transcription factors that may frequently
regulate target genes altered in mutant, compared to wild-type, striatal
cells (HD CAG) or 3-NP treated, compared to untreated wild-type, striatal
cells (3-NP), showing ES and FDR q-value statistic.
doi:10.1371/journal.pgen.0030135.g007
PLoS Genetics | www.plosgenetics.org August 2007 | Volume 3 | Issue 8 | e135 1404
HD CAG Does Not Directly Inhibit the Mitochondrionments. JML, EVI, ISS, TC, IK, and MEM analyzed the data. JML and
MEM wrote the paper, incorporating comments from EVI, ISS, TC,
IK, and JFG. IK, JFG, and MEM obtained the funding to support the
work.
Funding. This work was supported by National Institutes of Health
Center for Biomedical Computing grant LM008748 (IK); National
Institute of Neurological Disorders and Stroke grants NS16367 (JFG
and MEM, HD Center Without Walls), and NS32765 (MEM); an
anonymous donor; and the Huntington’s Disease Society of America
(Coalition for the Cure).
Competing interests. The authors have declared that no competing
interests exist.
References
1. The Huntington’s Disease Collaborative Research Group (1993) A novel
gene containing a trinucleotide repeat that is expanded and unstable on
Huntington’s disease chromosomes. Cell 72: 971–983.
2. Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, et al. (1985)
Neuropathological classiﬁcation of Huntington’s disease. J Neuropathol
Exp Neurol 44: 559–577.
3. Borlongan CV, Koutouzis TK, Sanberg PR (1997) 3-Nitropropionic acid
animal model and Huntington’s disease. Neurosci Biobehav Rev 21: 289–
293.
4. Kuhl DE, Phelps ME, Markham CH, Metter EJ, Riege WH, et al. (1982)
Cerebral metabolism and atrophy in Huntington’s disease determined by
18FDG and computed tomographic scan. Ann Neurol 12: 425–434.
5. Mazziotta JC, Phelps ME, Pahl JJ, Huang SC, Baxter LR, et al. (1987)
Reduced cerebral glucose metabolism in asymptomatic subjects at risk for
Huntington’s disease. N Engl J Med 316: 357–362.
6. Grafton ST, Mazziotta JC, Pahl JJ, St George-Hyslop P, Haines JL, et al.
(1990) A comparison of neurological, metabolic, structural, and genetic
evaluations in persons at risk for Huntington’s disease. Ann Neurol 28:
614–621.
7. Jenkins BG, Koroshetz WJ, Beal MF, Rosen BR (1993) Evidence for
impairment of energy metabolism in vivo in Huntington’s disease using
localized 1H NMR spectroscopy. Neurology 43: 2689–2695.
8. Jenkins BG, Rosas HD, Chen YC, Makabe T, Myers R, et al. (1998) 1H NMR
spectroscopy studies of Huntington’s disease: Correlations with CAG
repeat numbers. Neurology 50: 1357–1365.
9. Koroshetz WJ, Jenkins BG, Rosen BR, Beal MF (1997) Energy metabolism
defects in Huntington’s disease and effects of coenzyme Q10. Ann Neurol
41: 160–165.
10. Lodi R, Schapira AH, Manners D, Styles P, Wood NW, et al. (2000)
Abnormal in vivo skeletal muscle energy metabolism in Huntington’s
disease and dentatorubropallidoluysian atrophy. Ann Neurol 48: 72–76.
11. Saft C, Zange J, Andrich J, Muller K, Lindenberg K, et al. (2005)
Mitochondrial impairment in patients and asymptomatic mutation carriers
of Huntington’s disease. Mov Disord 20: 674–679.
12. Seong IS, Ivanova E, Lee JM, Choo YS, Fossale E, et al. (2005) HD CAG
repeat implicates a dominant property of huntingtin in mitochondrial
energy metabolism. Hum Mol Genet 14: 2871–2880.
13. Clabough EB, Zeitlin SO (2006) Deletion of the triplet repeat encoding
polyglutamine within the mouse Huntington’s disease gene results in subtle
behavioral/motor phenotypes in vivo and elevated levels of ATP with
cellular senescence in vitro. Hum Mol Genet 15: 607–623.
14. McGill JK, Beal MF (2006) PGC-1alpha, a new therapeutic target in
Huntington’s disease? Cell 127: 465–468.
15. Choo YS, Johnson GV, MacDonald M, Detloff PJ, Lesort M (2004) Mutant
huntingtin directly increases susceptibility of mitochondria to the calcium-
induced permeability transition and cytochrome c release. Hum Mol Genet
13: 1407–1420.
16. Panov AV, Gutekunst CA, Leavitt BR, Hayden MR, Burke JR, et al. (2002)
Early mitochondrial calcium defects in Huntington’s disease are a direct
effect of polyglutamines. Nat Neurosci 5: 731–736.
17. Panov AV, Burke JR, Strittmatter WJ, Greenamyre JT (2003) In vitro effects
of polyglutamine tracts on Ca2þ-dependent depolarization of rat and
human mitochondria: relevance to Huntington’s disease. Arch Biochem
Biophys 410: 1–6.
18. Trettel F, Rigamonti D, Hilditch-Maguire P, Wheeler VC, Sharp AH, et al.
(2000) Dominant phenotypes produced by the HD mutation in
STHdh(Q111) striatal cells. Hum Mol Genet 9: 2799–2809.
19. Cui L, Jeong H, Borovecki F, Parkhurst CN, Tanese N, et al. (2006)
Transcriptional repression of PGC-1alpha by mutant huntingtin leads to
mitochondrial dysfunction and neurodegeneration. Cell 127: 59–69.
20. Weydt P, Pineda VV, Torrence AE, Libby RT, Satterﬁeld TF, et al. (2006)
Thermoregulatory and metabolic defects in Huntington’s disease trans-
genic mice implicate PGC-1alpha in Huntington’s disease neurodegenera-
tion. Cell Metab 4: 349–362.
21. Milakovic T, Johnson GV (2005) Mitochondrial respiration and ATP
production are signiﬁcantly impaired in striatal cells expressing mutant
huntingtin. J Biol Chem 280: 30773–30782.
22. Gines S, Seong IS, Fossale E, Ivanova E, Trettel F, et al. (2003) Speciﬁc
progressive cAMP reduction implicates energy deﬁcit in presymptomatic
Huntington’s disease knock-in mice. Hum Mol Genet 12: 497–508.
23. Mao Z, Choo YS, Lesort M (2006) Cystamine and cysteamine prevent 3-NP-
induced mitochondrial depolarization of Huntington’s disease knock-in
striatal cells. Eur J Neurosci 23: 1701–1710.
24. Nasr P, Gursahani HI, Pang Z, Bondada V, Lee J, et al. (2003) Inﬂuence of
cytosolic and mitochondrial Ca2þ, ATP, mitochondrial membrane poten-
tial, and calpain activity on the mechanism of neuron death induced by 3-
nitropropionic acid. Neurochem Int 43: 89–99.
25. Tian L, Greenberg SA, Kong SW, Altschuler J, Kohane IS, et al. (2005)
Discovering statistically signiﬁcant pathways in expression proﬁling
studies. Proc Natl Acad Sci U S A 102: 13544–13549.
26. Sipione S, Rigamonti D, Valenza M, Zuccato C, Conti L, et al. (2002) Early
transcriptional proﬁles in huntingtin-inducible striatal cells by microarray
analyses. Hum Mol Genet 11: 1953–1965.
27. Almeida A, Moncada S, Bolanos JP (2004) Nitric oxide switches on glycolysis
through the AMP protein kinase and 6-phosphofructo-2-kinase pathway.
Nat Cell Biol 6: 45–51.
28. Calvo S, Jain M, Xie X, Sheth SA, Chang B, et al. (2006) Systematic
identiﬁcation of human mitochondrial disease genes through integrative
genomics. Nat Genet 38: 576–582.
29. Hodges A, Strand AD, Aragaki AK, Kuhn A, Sengstag T, et al. (2006)
Regional and cellular gene expression changes in human Huntington’s
disease brain. Hum Mol Genet 15: 965–977.
30. White JK, Auerbach W, Duyao MP, Vonsattel JP, Gusella JF, et al. (1997)
Huntingtin is required for neurogenesis and is not impaired by the
Huntington’s disease CAG expansion. Nat Genet 17: 404–410.
31. Reiner A, Dragatsis I, Zeitlin S, Goldowitz D (2003) Wild-type huntingtin
plays a role in brain development and neuronal survival. Mol Neurobiol 28:
259–276.
32. Van Raamsdonk JM, Gibson WT, Pearson J, Murphy Z, Lu G, et al. (2006)
Body weight is modulated by levels of full-length huntingtin. Hum Mol
Genet 15: 1513–1523.
33. Woda JM, Calzonetti T, Hilditch-Maguire P, Duyao MP, Conlon RA, et al.
(2005) Inactivation of the Huntington’s disease gene (Hdh) impairs anterior
streak formation and early patterning of the mouse embryo. BMC Dev Biol
5: 17.
34. Dragatsis I, Efstratiadis A, Zeitlin S (1998) Mouse mutant embryos lacking
huntingtin are rescued from lethality by wild-type extraembryonic tissues.
Development 125: 1529–1539.
35. Hilditch-Maguire P, Trettel F, Passani LA, Auerbach A, Persichetti F, et al.
(2000) Huntingtin: An iron-regulated protein essential for normal nuclear
and perinuclear organelles. Hum Mol Genet 9: 2789–2797.
36. MacDonald ME (2003) Huntingtin: Alive and well and working in middle
management. Sci STKE 2003: pe48.
37. Zuccato C, Tartari M, Crotti A, Goffredo D, Valenza M, et al. (2003)
Huntingtin interacts with REST/NRSF to modulate the transcription of
NRSE-controlled neuronal genes. Nat Genet 35: 76–83.
38. Desaint S, Hansmannel F, Clemencet MC, Le Jossic-Corcos C, Nicolas-
Frances V, et al. (2004) NFY interacts with the promoter region of two
genes involved in the rat peroxisomal fatty acid beta-oxidation: the
multifunctional protein type 1 and the 3-ketoacyl-CoA B thiolase. Lipids
Health Dis 3: 4.
39. Droge W (2006) Redox regulation in anabolic and catabolic processes. Curr
Opin Clin Nutr Metab Care 9: 190–195.
40. Hernandez-Montes E, Pollard SE, Vauzour D, Jofre-Montseny L, Rota C, et
al. (2006) Activation of glutathione peroxidase via Nrf1 mediates genistein’s
protection against oxidative endothelial cell injury. Biochem Biophys Res
Commun 346: 851–859.
41. Li SH, Cheng AL, Zhou H, Lam S, Rao M, et al. (2002) Interaction of
Huntington disease protein with transcriptional activator Sp1. Mol Cell
Biol 22: 1277–1287.
42. Zhai W, Jeong H, Cui L, Krainc D, Tjian R (2005) In vitro analysis of
huntingtin-mediated transcriptional repression reveals multiple transcrip-
tion factor targets. Cell 123: 1241–1253.
43. Chen-Plotkin AS, Sadri-Vakili G, Yohrling GJ, Braveman MW, Benn CL, et
al. (2006) Decreased association of the transcription factor Sp1 with genes
downregulated in Huntington’s disease. Neurobiol Dis 22: 233–241.
44. Takano H, Gusella JF (2002) The predominantly HEAT-like motif structure
of huntingtin and its association and coincident nuclear entry with dorsal,
an NF-kB/Rel/dorsal family transcription factor. BMC Neurosci 3: 15.
45. Matthews JR, Wakasugi N, Virelizier JL, Yodoi J, Hay RT (1992)
Thioredoxin regulates the DNA binding activity of NF-kappa B by
reduction of a disulphide bond involving cysteine 62. Nucleic Acids Res
20: 3821–3830.
46. Baughman JM, Mootha VK (2006) Buffering mitochondrial DNA variation.
Nat Genet 38: 1232–1233.
47. Levine S, Gregory C, Nguyen T, Shrager J, Kaiser L, et al. (2002)
Bioenergetic adaptation of individual human diaphragmatic myoﬁbers to
severe COPD. J Appl Physiol 92: 1205–1213.
48. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data
using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.
Methods 25: 402–408.
PLoS Genetics | www.plosgenetics.org August 2007 | Volume 3 | Issue 8 | e135 1405
HD CAG Does Not Directly Inhibit the Mitochondrion49. Bolstad BM, Irizarry RA, Astrand M, Speed TP (2003) A comparison of
normalization methods for high density oligonucleotide array data based
on variance and bias. Bioinformatics 19: 185–193.
50. Storey JD, Tibshirani R (2003) Statistical signiﬁcance for genomewide
studies. Proc Natl Acad Sci U S A 100: 9440–9445.
51. Dennis G Jr., Sherman BT, Hosack DA, Yang J, Gao W, et al. (2003) DAVID:
Database for annotation, visualization, and integrated discovery. Genome
Biol 4: P3.
52. Eisen MB, Spellman PT, Brown PO, Botstein D (1998) Cluster analysis and
display of genome-wide expression patterns. Proc Natl Acad Sci U S A 95:
14863–14868.
53. Li C, Wong WH (2001) Model-based analysis of oligonucleotide arrays:
expression index computation and outlier detection. Proc Natl Acad Sci U
S A 98: 31–36.
54. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, et al. (2004)
Bioconductor: open software development for computational biology and
bioinformatics. Genome Biol 5: R80.
55. Marinescu VD, Kohane IS, Riva A (2005) The MAPPER database: A multi-
genome catalog of putative transcription factor binding sites. Nucleic Acids
Res 33: D91–D97.
56. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, et al. (2005)
Gene set enrichment analysis: A knowledge-based approach for interpret-
ing genome-wide expression proﬁles. Proc Natl Acad Sci U S A 102: 15545–
15550.
PLoS Genetics | www.plosgenetics.org August 2007 | Volume 3 | Issue 8 | e135 1406
HD CAG Does Not Directly Inhibit the Mitochondrion